KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Ravulizumab for the treatment of myasthenia gravis.

Fiammetta Vanoli, Renato Mantegazza

Expert Opin Biol Ther 23(3) 235-241

PMID36852670
PMCID-
DOI10.1080/14712598.2023.2185131
发表日期2023-02-28
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

INTRODUCTION: Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder affecting the neuromuscular junction. MG therapeutics have always relied on nonselective immunosuppression with oral steroids and non-steroidal immunosuppressants, mainly with good clinical response. However, clinical stabilization is often reached at the cost of many troublesome side effects and up to 15% of MG patients are deemed as refractory to conventional immunosuppression. This highlights the need of a more targeted and efficacious therapeutic approach. Results from the randomized-controlled period of the CHAMPION study demonstrate a good safety, tolerability, and efficacy profile of ravulizumab compared to placebo. Like eculizumab, ravulizumab is an anti-C5 monoclonal antibody, but with an enhanced pharmacokinetic profile, that allows dosing every 8 weeks. AREAS COVERED: We provide an overview of ravulizumab biological features and results from the phase III CHAMPION MG (NCT03920293) study. EXPERT OPINION: Data of the CHAMPION MG trial demonstrate that ravulizumab is effective and safe in the treatment of generalized MG. Having a rapid clinical effect, with long-term clinical response, ravulizumab could represent a selective immunosuppressive drug of choice in the future therapeutic algorithm of MG, where conventional immunosuppressants slowly leave room for newer drugs with a more targeted mechanism of action.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。